Global Insulin Market Size Grows at a CAGR of 3.63%

Introduction

Straits Research released its highly anticipated report, “Global Insulin Market Size & Outlook, 2026-2034.” According to the study, the global market size is valued at USD 21.13 billion in 2025 and is projected to expand to USD 29.01 billion by 2034, registering a compound annual growth rate (CAGR) of 3.63%.

Market Dynamics

The market growth is primarily attributed to the rising prevalence of diabetes and continuous innovations in insulin formulations, including long-acting and rapid-acting therapies, which improve patient adherence and clinical outcomes. In addition, the expansion of production capacity by leading pharmaceutical companies is driving growth in the global insulin market. For instance, in December 2024, Sanofi announced it planned to invest USD 1.1 billion in constructing a new insulin production facility in Beijing's Economic and Technological Development Zone, marking its largest investment in China to date. This facility was Sanofi's fourth production and supply center in the country, enhancing local insulin production capacity and meeting growing demand. Such expansion strengthened the global insulin supply chain, improved accessibility, and supported the market’s sustained growth in response to increasing diabetes prevalence. However, the insulin market faced a major restraint due to its high cost, which remained a significant barrier for patients in low and middle-income countries. Despite of these challenges, the market presented significant opportunities, such as the growing adoption of smart insulin delivery devices, which represented a significant opportunity for the global insulin market. These connected systems, such as smart pens, patch pumps, and closed-loop automation, harness AI-driven insights to optimize dosing and improve patient adherence. Furthermore, increasing awareness and acceptance of these advanced technologies, especially in developed regions, is expected to expand the widespread adoption and create new avenues for market growth.

Market Highlights

• Type: The Human Insulin is expected to witness the highest CAGR (4.69%) during the forecast period.
• Product: According to Straits Research, the Long-Acting Insulin segment dominated the market in 2025, with a revenue share of 49.84%.
• Application: Type II Diabetes segment is expected to witness the highest CAGR (5.03%) during the forecast period.
• Distribution Channel: The Hospitals segment dominated the market in 2025, fuelled by high patient inflow, availability of specialized care, and preference for in-hospital insulin administration.
• Regional Insights: North America dominates with over 43.06% share, driven by increasing adoption of advanced insulin devices.

Competitive Players

1. Novo Nordisk A/S
2. Eli Lilly and Company
3. Sanofi
4. Biocon
5. Wockhardt
6. Boehringer Ingelheim International GmbH
7. Julphar Diabetes
8. The United Laboratories International Holdings Limited.
9. Tonghua Dongbao Pharmaceutical Co., Ltd.
10. Medtronic
11. Merck & Co., Inc.
12. BD
13. Tandem Diabetes Care, Inc.
14. Ypsomed Diabetes Care AG
15. UNDBIO Co., Ltd.
16. Insulet Corporation
17. Lantus
18. Bioton S.A.

Recent Developments

Segmentation

1. By Type (2026-2034)
   1. Human Insulin
   2. Analog Insulin
2. By Product (2026-2034)
   1. Short-Acting Insulin
   2. Intermediate Acting Insulin
   3. Long-Acting Insulin
   4. Fast-Acting Insulin
3. By Applications (2026-2034)
   1. Type I Diabetes
   2. Type II Diabetes
   3. Gestational Diabetes
   4. Pre-diabetes
4. By Distribution Channel (2026-2034)
   1. Hospitals
   2. Drug Stores & Retail Pharmacies
   3. Others